ASPN Stock Cash Flow Statements

Aspen Aerogels Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Aspen Aerogels Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30

cash flows from operating activities:
net income	-9,056,000	-301,249,000	11,362,000	-12,970,000	16,818,000	-1,835,000	-519,000	-13,073,000	-15,423,000	-16,796,000	-9,609,000	-29,595,000	-24,050,000	-19,484,000	-16,353,000	-7,822,000	-6,669,000	-6,250,000	-6,189,000	-6,753,000	-5,698,000	-3,169,000	-956,000	-2,289,000	-5,318,000	-6,002,000	-14,108,000	-6,532,000	-6,958,000	-6,842,000	-1,683,000	-3,088,000	-5,472,000	-9,078,000	-5,742,000	-3,097,000	-1,387,000	-1,797,000	1,638,000	-2,523,000	-2,742,000	-2,790,000	-2,717,000	-2,411,000
adjustments to reconcile net income to net cash from operating activities:
depreciation	5,796,000	5,793,000	5,433,000	5,321,000	5,986,000	5,786,000	4,561,000	4,550,000	3,503,000	2,704,000	2,530,000	2,531,000	2,033,000	2,128,000	2,584,000	2,114,000	2,104,000	2,638,000	2,528,000
accretion of interest on convertible note - related party			0	1,463,000	2,810,000	2,810,000	2,682,000				1,007,000	1,734,000	1,550,000	819,000
amortization of debt issuance costs	882,000	730,000													0	11,000	4,000	3,000	3,000	4,000
amortization of debt discount due to modification of convertible note – related party			0	0	224,000	219,000	213,000	206,000	203,000	266,000
deferred financing costs written off			0	0	120,000	1,709,000
benefit from bad debt	140,000	-108,000	108,000	-1,000			-4,000	-17,000	-171,000	99,000	73,000	43,000	4,000	-5,000	12,000	1,000	-3,000	-95,000	154,000
stock-based compensation expense	2,815,000	1,952,000	2,548,000	2,630,000
impairment of property, plant and equipment	1,387,000	286,634,000	803,000	0	771,000	6,039,000
reduction in the carrying amount of operating lease right-of-use assets	1,192,000	652,000	-104,000	767,000	649,000	574,000	673,000	781,000	773,000	632,000	715,000	706,000	649,000	570,000	561,000	537,000	263,000	257,000	252,000	247,000	229,000	243,000
changes in operating assets and liabilities:
accounts receivable	1,048,000	31,857,000	5,987,000	1,730,000	-33,039,000	-14,034,000	-15,578,000	-10,229,000	3,284,000	9,971,000	-30,309,000	2,321,000	-4,952,000	-4,102,000	-1,715,000	642,000	1,305,000	-4,875,000	4,220,000	-1,075,000	1,287,000	11,799,000	-7,892,000	-2,196,000	121,000	3,278,000	-7,026,000	-1,355,000	28,000	6,630,000	-9,648,000	-574,000	1,076,000	442,000	2,090,000	5,109,000	-1,819,000	-2,291,000	2,781,000	-3,392,000	-697,000	-1,336,000	2,143,000	-1,518,000
inventories	4,624,000	-9,188,000	-121,000	5,600,000	-7,280,000	-6,561,000	-4,768,000	-1,132,000	-6,282,000	-4,469,000	-1,938,000	-3,600,000	-1,495,000	-3,518,000	-2,275,000	-274,000	1,409,000	2,252,000	-3,672,000	25,000	3,980,000	-4,664,000	4,691,000	-360,000	-3,831,000	-1,950,000	2,591,000	2,913,000	-2,848,000	-1,059,000	5,077,000	-737,000	1,877,000	-2,264,000	34,000	-1,114,000	-5,649,000	393,000	97,000	-554,000	-170,000	-1,008,000	1,452,000	-859,000
prepaid expenses and other assets	1,928,000	12,854,000	-3,049,000	-3,980,000	-3,447,000	-9,359,000	-630,000	-259,000	-1,415,000	-5,097,000	-100,000	-555,000	-2,126,000	-374,000	221,000	-1,371,000	-1,804,000	630,000	-231,000	-198,000	-468,000	181,000	400,000	-203,000	-408,000	127,000	372,000	-217,000	-98,000	204,000	187,000	-125,000	-148,000	497,000	-208,000	234,000	-1,011,000	966,000	120,000	266,000	-928,000	-339,000	214,000	93,000
accounts payable	-10,714,000	-3,865,000	2,889,000	-13,062,000	15,366,000	2,148,000	5,003,000	987,000	4,109,000	-5,516,000	4,837,000	-15,499,000	12,917,000	3,063,000	3,609,000	-192,000	2,530,000	1,432,000	-3,355,000	3,752,000	-3,814,000	-3,732,000	3,006,000	-1,042,000	1,886,000	-3,709,000	4,867,000	-1,102,000	1,132,000	-3,340,000	1,747,000	794,000	-3,510,000	2,238,000	122,000	-1,476,000	-49,000	1,508,000	13,000	327,000	1,648,000	-471,000	-88,000	858,000
accrued expenses	-1,117,000	-19,814,000	9,965,000	6,847,000	5,332,000	-10,289,000	6,117,000	6,022,000	909,000	-6,240,000	3,266,000	1,764,000	3,236,000	-3,082,000	1,028,000	2,872,000	1,661,000	1,422,000	-197,000	-11,000	476,000	-4,441,000	3,518,000	494,000	-185,000	517,000	249,000	-1,167,000	785,000	-1,923,000	1,069,000	-61,000	688,000	125,000	11,000	-714,000	728,000	-2,203,000	896,000	384,000	756,000	-2,263,000	883,000	1,514,000
deferred revenue	-2,021,000	446,000	-206,000	-690,000	-35,000	814,000	-3,147,000	829,000	660,000	-1,872,000	3,490,000	740,000	415,000	-120,000	-288,000	-63,000	-223,000	31,000	-251,000	-1,245,000	-1,467,000	-851,000	-1,478,000	-1,757,000	5,224,000	1,403,000	-543,000	1,244,000	454,000	-345,000	-304,000	802,000	17,000	-254,000	290,000	304,000	310,000	-542,000	-3,834,000	1,928,000	1,169,000	1,070,000	-1,148,000	481,000
operating lease liabilities	-834,000	-1,062,000	-774,000	-672,000	-553,000	-485,000	-579,000	-687,000	-549,000	-609,000	-723,000	-645,000	-520,000	-556,000	-575,000	-325,000	-304,000	-293,000	-286,000	-281,000	-263,000	-274,000	-275,000	-273,000	-224,000	-246,000
net cash from operating activities	-3,930,000	5,632,000			6,843,000	-17,749,000	-2,779,000	-7,502,000	-7,680,000	-24,651,000	-24,080,000	-37,455,000	-10,035,000	-22,829,000	-12,049,000	-6,050,000	1,343,000	-1,872,000	-5,142,000	-1,540,000	-1,889,000	-1,353,000	4,707,000	-3,818,000	1,068,000	-3,011,000	86,000	-2,493,000	-3,849,000	-2,398,000	344,000	1,053,000	-1,584,000	-4,419,000	788,000	3,848,000	-5,000,000	-214,000	5,441,000	561,000	3,015,000	-3,658,000	4,718,000	1,739,000
cash flows from investing activities:
capital expenditures	-12,885,000	-12,998,000	-14,751,000	-20,821,000	-24,827,000	-25,863,000	-27,786,000	-32,279,000	-66,012,000	-49,378,000	-58,626,000	-66,989,000	-37,855,000	-14,504,000	-7,645,000	-2,254,000	-2,409,000	-1,470,000	-816,000	-623,000	-1,050,000	-927,000	-523,000	-287,000	-665,000	-637,000	-942,000	-994,000	-980,000	-677,000	-695,000	-592,000	-2,685,000	-2,146,000	-3,222,000	-2,266,000	-4,600,000	-3,128,000	-2,579,000	-2,418,000	-6,428,000	-10,531,000	-8,631,000	-2,413,000
free cash flows	-16,815,000	-7,366,000			-17,984,000	-43,612,000	-30,565,000	-39,781,000	-73,692,000	-74,029,000	-82,706,000	-104,444,000	-47,890,000	-37,333,000	-19,694,000	-8,304,000	-1,066,000	-3,342,000	-5,958,000	-2,163,000	-2,939,000	-2,280,000	4,184,000	-4,105,000	403,000	-3,648,000	-856,000	-3,487,000	-4,829,000	-3,075,000	-351,000	461,000	-4,269,000	-6,565,000	-2,434,000	1,582,000	-9,600,000	-3,342,000	2,862,000	-1,857,000	-3,413,000	-14,189,000	-3,913,000	-674,000
net cash from investing activities	-12,885,000	-12,998,000	-14,751,000	-20,821,000	-24,827,000	-25,863,000	-27,786,000	-32,279,000	-66,012,000	-49,378,000	-58,626,000	-66,989,000	-37,855,000	-14,504,000	-7,645,000	-2,254,000	-2,409,000	-1,470,000	-816,000	-623,000	-1,050,000	-927,000	-523,000	-287,000	-665,000	-637,000	-942,000	-994,000	-980,000	-677,000	-695,000	-592,000	-2,685,000	-2,146,000	-3,222,000	-2,266,000	-4,600,000	-3,128,000	-2,579,000	86,000	-6,431,000	-13,032,000	-8,631,000	-2,413,000
cash flows from financing activities:
proceeds from employee stock option exercises			-7,000	287,000	8,698,000	1,386,000	1,214,000	274,000	150,000	21,000	379,000	0	136,000	38,000	772,000	836,000	230,000	463,000	1,674,000	118,000
proceeds from sale and leaseback transactions			1,000	10,000,000	0	4,982,000
repayment of lease and other finance obligations	-1,261,000	-1,203,000
payments made for employee restricted stock tax withholdings	-46,000	-556,000	-31,000	-124,000	-53,000	-1,081,000	-18,000	-9,000	-8,000	-385,000	-22,000	-1,000	-24,000	-2,315,000	-36,000	0	-64,000	-2,613,000	-8,000	0	-16,000	-1,195,000	-6,000	0	-10,000	-454,000		-28,000	0	-504,000		-99,000	0	-286,000		-114,000	0	-82,000
repayment of revolving line of credit	0	-13,200,000
repayment of term loan	-6,500,000	-6,500,000
fees and issuance costs from offering of common stock	-10,000	-18,000
net cash from financing activities	-7,586,000	-21,477,000	86,460,000	22,158,000	8,141,000	5,259,000	75,573,000	126,000	142,000	-364,000	262,869,000	44,657,000	4,898,000	165,946,000	727,000	1,578,000	86,104,000	4,065,000	11,140,000	118,000	4,512,000	10,433,000	-1,746,000	1,978,000	-450,000	3,690,000	-994,000	1,378,000	2,500,000	1,996,000	3,740,000	-107,000	-8,000	-293,000	-609,000	-190,000	-20,000	-105,000	-22,000	-258,000	-19,000	-19,000	-19,000	-2,592,000
net decrease in cash, cash equivalents and restricted cash	-24,401,000	-28,843,000		22,108,000
cash, cash equivalents and restricted cash at beginning of period	0	221,276,000	0	0	0	139,971,000	0	0	0	282,561,000
cash, cash equivalents and restricted cash at end of period	-24,401,000	192,433,000	107,393,000	22,108,000	-9,843,000	101,618,000	45,008,000
supplemental disclosures of cash flow information:
interest paid	3,178,000	3,385,000	4,679,000	2,305,000	-164,000	187,000	0	0			23,000	35,000	43,000	52,000	68,000	55,000	48,000	65,000	48,000	43,000	41,000	84,000	107,000	135,000	102,000	96,000	101,000	96,000	42,000	99,000	69,000	62,000	49,000	40,000	43,000	48,000	53,000	52,000	49,000	50,000	54,000	45,000	57,000	32,000
income taxes paid	384,000	2,916,000
supplemental disclosures of non-cash activities:
right-of-use assets obtained in exchange for new operating lease liabilities			278,000	2,370,000	2,389,000	94,000	386,000	115,000			-2,827,000	275,000	5,514,000	68,000	1,981,000	1,079,000	8,144,000	888,000	28,000	0	237,000	152,000	0	59,000	141,000	153,000
changes in accrued capital expenditures	-2,213,000	-565,000	-808,000	-1,904,000	-2,833,000	-8,529,000	8,976,000	-11,935,000	-8,868,000	3,610,000	-8,432,000	22,696,000	8,140,000	9,566,000	4,011,000	481,000	33,000	176,000	352,000	-111,000	-190,000	-147,000	493,000	111,000	-429,000	-112,000	-359,000	591,000	231,000	-281,000	20,000	-316,000	-2,251,000	-1,134,000	1,514,000	697,000	-579,000	484,000	780,000	-524,000	-5,247,000	-341,000	-446,000	6,795,000
amortization of convertible note issuance costs			-296,000	301,000	10,000	9,000	9,000	10,000	9,000	9,000	9,000	10,000	9,000	4,000
loss on extinguishment of debt			0
proceeds from underwritten public offering, net of underwriting discounts, commissions and issuance costs
proceeds from issuance of convertible note related party											0	0	0	100,000,000
issuance costs from convertible note											0	0	0	-185,000
proceeds from at-the-market offering net of commissions, fees and issuance costs of 2,885
proceeds from registered direct offering of common stock
fees and issuance costs from registered direct offering of common stock
proceeds from private placement of common stock											0	0	0	50,000,000	0
fees and issuance costs from private placement of common stock				0	0	-28,000	0				0	-1,000	0	-136,000	-9,000
repayment of convertible note			0
proceeds from term loan			0
issuance costs from term loan and revolver
proceeds from revolver			0
repayment of finance obligation for sale and leaseback transactions			-25,000	-339,000
repayment of prepayment liability											-5,000,000	0	0	-4,728,000
net increase in cash, cash equivalents and restricted cash						-38,353,000	45,008,000	-39,655,000	-73,550,000	-74,393,000
capitalized interest							0	962,000	2,561,000	2,561,000	1,446,000	753,000															18,000	17,000															0	0
increase in debt discount due to modification of convertible note – related party
net cash provided (use) in operating activities
issuance costs from term loan
issuance costs from revolver
stock-compensation expense						4,706,000		2,789,000	2,710,000	2,267,000		2,590,000	2,295,000	1,828,000		1,554,000	1,070,000	976,000		991,000	1,007,000	992,000		1,011,000	996,000	878,000		1,128,000	1,150,000	1,136,000		1,364,000	1,374,000	1,244,000
gain on extinguishment of debt															0
stock compensation expense																																					1,433,000	1,370,000	1,238,000	1,476,000	1,404,000	1,295,000	1,383,000	1,054,000
other liabilities																			-132,000	288,000			0	0	0	-56,000
proceeds from underwritten public offering, net of underwriting discounts and commissions
issuance costs from underwritten public offering																			0	0	0	-285,000
proceeds from at-the-market offering net of commissions and fees of 2,269 and 601
fees and issuance costs from at-the-market offering											15,000	-285,000	-28,000	-318,000
proceeds from issuance of convertible note - related party
proceeds from at-the-market offering, net of commissions of 2,269
proceeds from at-the-market offering, net of commissions of 879
cash, cash equivalents, restricted cash and restricted cash equivalents at end of period									-73,550,000	208,168,000
proceeds from at-the-market offering, net of commissions of 729
proceeds from issuance of long-term debt																			0	0
issuance costs from long-term debt																			0	0
repayments of borrowings under line of credit																					0	-3,123,000
proceeds from at-the-market offering, net of commissions of 2,269 and 601
net increase in cash												-59,787,000	-42,992,000	128,613,000	-18,967,000	-6,726,000	85,038,000	723,000	5,182,000	-2,045,000	1,573,000	8,153,000				42,000													2,840,000	389,000			-3,932,000	-3,266,000
cash and cash equivalents at beginning of period												0	0	76,564,000	0	0	0	16,496,000	0	0	0	3,633,000	0	0	0	3,327,000												32,804,000				49,719,000
cash and cash equivalents at end of period												-59,787,000	-42,992,000	205,177,000	-18,967,000	-6,726,000	85,038,000	17,219,000	5,182,000	-2,045,000	1,573,000	11,786,000	2,438,000	-2,127,000	-47,000	3,369,000												29,357,000				33,010,000
proceeds from at-the-market offering, net of commissions of 879 and 576
proceeds from at-the-market offering, net of commissions of 729 and 193														23,590,000
proceeds from underwritten public offering, net of underwriting discounts and commissions of 1,093																			0	0	0	15,036,000
prepayment proceeds under customer supply agreement																							0	0	0	5,000,000	0	0	2,500,000	2,500,000
proceeds from at-the-market offering net of commissions and fees of 601 and 299
issuance costs from at-the-market offering															0	1,000	-27,000	-17,000
initial recognition of operating lease liabilities related to right-of-use assets																							0	0	0	5,995,000
proceeds from at-the-market offering, net of commissions and fees of 601
proceeds from at-the-market offering, net of commissions and fees of 576
proceeds from private placement offering
fees and issuance costs from private placement offering
proceeds from at-the-market offering, net of commissions and fees of 193																		6,232,000
impairment of construction in process
lease incentives																											-30,000	-31,000	-30,000	-30,000	-31,000	-31,000	-27,000	-22,000
proceeds from at-the-market offering net of commissions and fees of 299
proceeds from (repayments of) borrowings under line of credit																			0
depreciation and amortization																					2,562,000	2,563,000	2,562,000	2,554,000	2,565,000	2,532,000	2,528,000	2,573,000	2,515,000	3,171,000	2,721,000	2,726,000	2,630,000	2,676,000	2,555,000	2,472,000	2,416,000	2,410,000	2,465,000	2,663,000	2,575,000	2,184,000	2,491,000	2,513,000
impairment of construction in progress
other																															0	0	0	-1,000				-13,000					1,000	-1,000
repayment of obligations under capital lease																															-4,000	-8,000	-8,000	-7,000	-13,000	-12,000	-20,000	-23,000	-22,000	-20,000	-19,000	-19,000	-19,000	-19,000
operating lease right-of-use assets																								243,000	242,000	217,000
proceeds from borrowings under line of credit																										36,914,000	25,741,000	18,859,000			21,250,000
net decrease in cash																								-2,127,000			-1,850,000	-2,109,000	-2,329,000	-1,079,000		354,000	-4,277,000	-6,858,000		1,392,000
repayment of borrowings under line of credit																									36,474,000	-37,770,000	-26,716,000	-17,453,000			-17,500,000
postponed financing costs
payments made for employee restricted stock minimum tax withholdings																																							0
accretion of prepayment discount																												64,000	33,000	10,000
deferred rent																												-11,000	-12,000	-10,000		-17,000	-89,000	-22,000
cash at beginning of period																												0	0	10,694,000		0	0	18,086,000		0				0			0	0
cash at end of period																												-2,109,000	-2,329,000	9,615,000		354,000	-4,277,000	11,228,000		1,392,000				389,000			-3,932,000	-3,266,000
cost of product revenue																												-4,000	8,000	154,000		-35,000	32,000	204,000		42,000
research and development expenses																												4,000	9,000	111,000		-9,000	22,000	138,000		36,000
sales and marketing expenses																												-3,000	-23,000	232,000		-9,000	35,000	268,000		37,000
general and administrative expenses																												-19,000	20,000	639,000		43,000	41,000	634,000		-74,000
total stock-based compensation																												-22,000	14,000	1,136,000		-10,000	130,000	1,244,000		41,000
purchase of marketable securities																																							0
maturity and sale of marketable securities																																							0
capital lease																																											0	0
payment of deferred financing costs
changes in building lease incentives
unpaid financing costs
settlement of asset retirement obligation
advanced billings																																						292,000
loss on disposal of assets																																											104,000	0
financing and debt issuance costs
accretion of debt to fair value																																											0	0
borrowings under line of credit																																											0	0
repayments under line of credit																																											0	0
repayment of borrowings under long-term debt
financing costs																																											0	-15,000
proceeds from initial public offering																																											0	-2,558,000
proceeds from issuance of common stock																																											0	0
conversion of convertible and senior convertible notes to common stock																																											-1,000	0
purchases of marketable securities																																									-3,000	-2,501,000
capitalized leases
other long-term liabilities																																						-15,000
net decrease in cash and cash equivalents																																						-3,447,000				-16,709,000
write-off of construction in progress
debt issuance costs and noncash interest expenses
write-off of costs associated with postponed public offering
gain on extinguishment of convertible notes
loss on exchange of convertible notes
issuance of series c preferred stock warrants in connection with senior convertible notes
accrued dividends on preferred stock
changes in redemption value of redeemable convertible preferred stock
reclassification of redeemable convertible preferred stock from temporary to permanent equity
debt issuance costs
repayment of borrowing under long-term debt																																												0
unpaid initial public offering costs
deferred offering costs
unpaid deferred initial public offering costs
decrease in restricted cash
revenue:
u.s.
international
total
debt issuance costs and non-cash interest expenses																																												15,000

We provide you with 20 years of cash flow statements for Aspen Aerogels stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Aspen Aerogels stock. Explore the full financial landscape of Aspen Aerogels stock with our expertly curated income statements.

The information provided in this report about Aspen Aerogels stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.